Marginal costs and benefits

David Torgerson(University of York), Anne Spencer(Dalhousie University)

BMJ

January 6, 1996

10.1136/bmj.312.7022.35

Cited by 49

Related Papers

The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women

|Osteoporosis International|2007|1.2k

Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial

|The Lancet|2005|976

CONSORT 2025 statement: updated guideline for reporting randomised trials

|BMJ|2025|847

Guidelines for diagnosis and management of osteoporosis

|Osteoporosis International|1997|793

Understanding controlled trials: What are pragmatic trials?

|BMJ|1998|721